Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
0.00%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
0.00%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Estrella Immunopharma, Inc.
Market Cap
$17.99M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$17.84M
Net Profit Margin
-33.08%
TTM Avg
-29.53%
3Y Avg
-30.32%
5Y Avg
-22.32%
Market Cap
$18.75M
Net Profit Margin
-1578.40%
TTM Avg
-574.01%
3Y Avg
-287.00%
5Y Avg
-1306.57%
Market Cap
$16.76M
Net Profit Margin
-63.54%
TTM Avg
-31.77%
3Y Avg
-305.26%
5Y Avg
2352.19%
Market Cap
$17.04M
Net Profit Margin
-10794.64%
TTM Avg
946.68%
3Y Avg
-6081.70%
5Y Avg
-5732.70%
Market Cap
$18.74M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$17.11M
Net Profit Margin
-755.13%
TTM Avg
-243.50%
3Y Avg
-516.28%
5Y Avg
-344.84%
Market Cap
$16.84M
Net Profit Margin
-706.23%
TTM Avg
-81.41%
3Y Avg
-315.86%
5Y Avg
-1797.64%
Market Cap
$16.87M
Net Profit Margin
-106.58%
TTM Avg
-228.29%
3Y Avg
-394.31%
5Y Avg
-410.59%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Estrella Immunopharma, Inc. (ESLA) | $17.99M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cosmos Health Inc. (COSM)vs › | $17.84M | -33.08% | -29.53% | -30.32% | -22.32% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.75M | -1578.40% | -574.01% | -287.00% | -1306.57% |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | -63.54% | -31.77% | -305.26% | 2352.19% |
| PAVmed Inc. (PAVM)vs › | $17.04M | -10794.64% | 946.68% | -6081.70% | -5732.70% |
| Actuate Therapeutics Inc (ACTU)vs › | $18.74M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lipocine Inc. (LPCN)vs › | $17.11M | -755.13% | -243.50% | -516.28% | -344.84% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | -706.23% | -81.41% | -315.86% | -1797.64% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.87M | -106.58% | -228.29% | -394.31% | -410.59% |
| P3 Health Partners Inc. (PIII)vs › | $19.43M | -6.55% | -9.60% | -12.37% | -13.41% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-02-28 | 0.00% |
